Diagnosing lynch syndrome: More light at the end of the tunnel

Cancer Prevention Research

Volumn 5, Issue 4, 2012, Pages 507-510

  Burt, Randall W ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMATOUS POLYP; CANCER DIAGNOSIS; CANCER TISSUE; GENE MUTATION; GENETIC ANALYSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; ADENOMA; BASE MISPAIRING; COLORECTAL TUMOR; DNA REPAIR; FEMALE; GENETICS; MALE; METABOLISM; MICROSATELLITE INSTABILITY; NOTE; POLYP;

ADENOMA; BASE PAIR MISMATCH; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; POLYPS;

EID: 84864856743     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0087     Document Type: Review

References (19)

1. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010;138:2044-58.
2. Yurgelun MB, Goel A, Hornick JL, Sen A, Turgeon DK, Ruffin MT IV, et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res 2012;5:574-82.
3. Edelstein DL, Axilbund J, Baxter M, Hylind LM, Romans K, Griffin CA, et al. Rapid development of colorectal neoplasia in patients with lynch syndrome. Clin Gastroenterol Hepatol 2011;9:340-3.
4. Weissman SM, Bellcross C, Bittner CC, Freivogel ME, Haidle JL, Kaurah P, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome-a review. J Genet Couns 2011;20:5-19.
5. Khan O, Blanco A, Conrad P, Gulden C, Moss TZ, Olopade OI, et al. Performance of lynch syndromepredictive models in a multi-center US referral population. Am J Gastroenterol 2011;106:1822-7.
6. Kastrinos F, Steyerberg EW, Mercado R, Balmaña J, Holter S, Gallinger S, et al. The PREMM1,2,6 model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73-81.e5.
7. Kastrinos F, Allen JI, Stockwell DH, Stoffel EM, Cook EF, Mutinga ML, et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol 2009;104:1508-18.
8. Pérez-Cabornero L, Infante Sanz M, Velasco Sampedro E, Lastra Aras E, Acedo Becares A, Miner Pino C, et al. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 50 part of MSH2. Cancer Prev Res 2011;4:1556-62.
9. Funkhouser WK, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas a report of the association of molecular pathology. J Mol Diagn 2012;14:91-103.
10. Xie J, Guillemette S, Peng M, Gilbert C, Buermeyer A, Cantor SB. An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy. Cancer Prev Res 2010;3:1409-16.
11. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69-79.
12. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93-104.
13. Bellcross CA, Bedrosian SR, Daniels E, Duquette D, Hampel H, Jasperson K, et al. Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: Summary of a public health/clinical collaborative meeting. Genet Med 2012;14:152-62.
14. Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010;8:8-61.
15. Gudgeon J, Williams JL, Burt RW, Samowitz WS, Snow GL, Williams MS. Lynch syndrome screening implementation: business analysis by a healthcare system. Am J Manag Care 2011;17:e288-e300.
16. Hampel H. Point: justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw 2010;8:597-601.
17. Backes FJ, Hampel H, Backes KA, Vaccarello L, Lewandowski G, Bell JA, et al. Are prediction models for Lynch syndrome valid for probands with endometrial cancer? Fam Cancer 2009;8:483-7.
18. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 2012;118:681-8.
19. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 2011;4:9-22.